Tag Archives: Canada

Merck to Close Eight Plants

By Oriana Schwindt | Published: July 8, 2010

Image by Getty Images via @daylife Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.” Taking a page out of Pfizer’s book [...]

Posted in Strategy | Also tagged business, Factory, Infectious disease, Merck, Research and development, Schering Plough, South America | 3 Comments

Pharma Unplugged #2 Layoffs & Bonuses

By George Koroneos | Published: December 7, 2009

Pharma Unplugged #2— Layoffs & Bonuses Recorded: 12/3/2009 Air Date: 12/7/2009 Host: George Koroneos, Pharm Exec Cohost: Reid Paul, Pharm Rep Magazine Show Notes: This week we discuss: Pfizer’s medical education relationship with the Canadian Medical Association Journalists take FDA to task for not being transparent enough Layoffs and job cuts at Sanofi-Aventis New report shows that DTC receives more funding than sales calls in [...]

Posted in News, Podcasts | Also tagged Food and Drug Administration, Medicine, pharma unplugged, podcast, Sanofi-Aventis | Leave a comment

H1N1 Vaccine Quantities to Fall Short of Predictions

By George Koroneos | Published: August 19, 2009

Image by â– Guerry via Flickr The US may not have as many H1N1 flu vaccines available from the get-go as originally anticipated, CBS News reported on Tuesday. According to the report, approximately 45 million doses will be available in mid-October—that’s down from the original plan of 120 million doses. The new plan calls for [...]

Posted in Manufacturing | Also tagged GlaxoSmithKline, Health, Influenza, Influenza A virus subtype H1N1, Influenza pandemic, Influenza vaccine | 2 Comments

GSK Signs $120M Deal to Market DMab Overseas

By George Koroneos | Published: July 29, 2009

Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval. GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]

Posted in Deals, News, Technology | Also tagged Amgen, Australia, denosumab, Dmab, GlaxoSmithKline, Market, Mexico, New Zealand, sales force, U.S. Food and Drug Administration, United States | 1 Comment